Drugs / VC004
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06619951 | Sep → Oct 2024 | — | Jiangsu vcare pharmaceutical technology co., LTD | Completed | No outcome recorded |
| Phase 1 | NCT06529445 | Jul → Aug 2024 | NTRK fusion positive cancer | Jiangsu vcare pharmaceutical technology co., LTD | Completed | No outcome recorded |
| Phase 1 | NCT05528120 | Oct 2022 | NTRK fusion positive cancer | Jiangsu vcare pharmaceutical technology co., LTD | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06658353 | Mar 2025 → Dec 2026 expected | — | Jiangsu vcare pharmaceutical technology co., LTD | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VC004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06658353 ↗ |
| Route | Oral | “Oral administration after fasting/high-fat meal” NCT05528120 ↗ |